- Home
- BJDX vs QLGN Comparison
BJDX vs QLGN Comparison
Compare BJDX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- QLGN
- Stock Information
- Founded
- BJDX 2015
- QLGN 1996
- Country
- BJDX United States
- QLGN United States
- Employees
- BJDX N/A
- QLGN N/A
- Industry
- BJDX Medical Specialities
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- QLGN Health Care
- Exchange
- BJDX Nasdaq
- QLGN Nasdaq
- Market Cap
- BJDX 2.9M
- QLGN 2.8M
- IPO Year
- BJDX 2021
- QLGN N/A
- Fundamental
- Price
- BJDX $1.62
- QLGN $3.26
- Analyst Decision
- BJDX
- QLGN
- Analyst Count
- BJDX 0
- QLGN 0
- Target Price
- BJDX N/A
- QLGN N/A
- AVG Volume (30 Days)
- BJDX 2.1M
- QLGN 10.4K
- Earning Date
- BJDX 08-13-2025
- QLGN 08-13-2025
- Dividend Yield
- BJDX N/A
- QLGN N/A
- EPS Growth
- BJDX N/A
- QLGN N/A
- EPS
- BJDX N/A
- QLGN N/A
- Revenue
- BJDX N/A
- QLGN N/A
- Revenue This Year
- BJDX N/A
- QLGN N/A
- Revenue Next Year
- BJDX $55.56
- QLGN N/A
- P/E Ratio
- BJDX N/A
- QLGN N/A
- Revenue Growth
- BJDX N/A
- QLGN N/A
- 52 Week Low
- BJDX $1.46
- QLGN $2.85
- 52 Week High
- BJDX $37.50
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- BJDX 45.25
- QLGN 35.57
- Support Level
- BJDX $1.59
- QLGN $3.37
- Resistance Level
- BJDX $1.72
- QLGN $3.70
- Average True Range (ATR)
- BJDX 0.09
- QLGN 0.23
- MACD
- BJDX 0.01
- QLGN -0.05
- Stochastic Oscillator
- BJDX 43.33
- QLGN 0.00
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.